AJANTA PHARMA LTD. - 532331 - Corporate Action-Board to consider Dividend
Board to consider declaration of 2nd Interim Dividend for the financial year ending 31st March 2024 in its Board Meeting scheduled to be held on Wednesday, 31st January 2024. AJANTA PHARMA LTD. - 532331 - Update on board meeting
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 ,inter alia, to consider and approve This is with reference to our letter dated 19th January 2024, informing about the Board meeting scheduled on Wednesday, 31st January 2024 to inter-alia consider and take on record the unaudited financial results for the third quarter ended 31st December 2023. Pursuant to Regulation 29(1)(e) of the Listing Regulations, we hereby inform that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 2nd interim dividend for the financial year ending 31st March 2024; b. fixation of Thursday, 8th Dec 2024 as the Record Date for the payment of 2nd interim dividend, if declared. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 31st January 2024, post Board meeting. AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Approving Financial Results
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 ,inter alia, to consider and approve Unaudited Consolidated and Standalone Financial Results for the third quarter ended 31.12.2023. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
PFA herewith newspaper publication w.r.t transfer of shares to IEPF. AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December 2023. AJANTA PHARMA LTD. - 532331 - Participation In Investor Conference
Pls find enclosed schedule of participation in Investor conference AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 02, 2024 for Aayush Agrawal, Trustee Aayush Agrawal Trust AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to SEBI (PIT) Regulations, 2015, the Trading Window shall remain closed from the close of business hours of Friday, 29th December 2023 till 48 hours after the declaration of Unaudited Financial Results for the third quarter and nine months ended 31st December 2023. AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
PFA intimation w.r.t issue of duplicate share certificate